CoChat

Early prediction of autoimmune (type 1) diabetes.

Open access
Regnell, Simon E., Lernmark, Åke · 2017 · Diabetologia

The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.

Abstract

Underlying type 1 diabetes is a genetic aetiology dominated by the influence of specific HLA haplotypes involving primarily the class II DR-DQ region. In genetically predisposed children with the DR4-DQ8 haplotype, exogenous factors, yet to be identified, are thought to trigger an autoimmune reaction against insulin, signalled by insulin autoantibodies as the first autoantibody to appear. In children with the DR3-DQ2 haplotype, the triggering reaction is primarily against GAD signalled by GAD autoantibodies (GADA) as the first-appearing autoantibody. The incidence rate of insulin autoantibodies as the first-appearing autoantibody peaks during the first years of life and declines thereafter. The incidence rate of GADA as the first-appearing autoantibody peaks later but does not decline. The first autoantibody may variably be followed, in an apparently non-HLA-associated pathogenesis, by a second, third or fourth autoantibody. Although not all persons with a single type of autoantibody progress to diabetes, the presence of multiple autoantibodies seems invariably to be followed by loss of functional beta cell mass and eventually by dysglycaemia and symptoms. Infiltration of mononuclear cells in and around the islets appears to be a late phenomenon appearing in the multiple-autoantibody-positive with dysglycaemia. As our understanding of the aetiology and pathogenesis of type 1 diabetes advances, the improved capability for early prediction should guide new strategies for the prevention of type 1 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-017-4308-1

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Proposed staging of type 1 diabetes. The aetiology is represented by a variable genetic and environmental risk. The pathogenesis is represented by three stages. In stage 1, beta cell autoantibodies are persistent, normoglycaemia prevails and there are no symptoms. During stage 2, the number of beta cell autoantibodies may affect the pathogenesis to induce dysglycaemia but there are still no diabetes symptoms. In stage 3, beta cell autoantibodies are still prevalent (some of them may have been lost) and there are symptoms of diabetes. The staging of type 1 diabetes pathogenesis was proposed by Insel et al [1] and the figure is adapted with permission from Insel et al [1]. © 2015 The American Diabetes Association
Fig. 1 Proposed staging of type 1 diabetes. The aetiology is represented by a variable genetic and environmental risk. The pathogenesis is represented by three stages. In stage 1, beta cell autoantibodies are persistent, normoglycaemia prevails and there are no symptoms. During stage 2, the number of beta cell autoantibodies may affect the pathogenesis to induce dysglycaemia but there are still no diabetes symptoms. In stage 3, beta cell autoantibodies are still prevalent (some of them may have been lost) and there are symptoms of diabetes. The staging of type 1 diabetes pathogenesis was proposed by Insel et al [1] and the figure is adapted with permission from Insel et al [1]. © 2015 The American Diabetes AssociationCC BY · PubMed Central
Fig. 2 Map of the HLA DR-DQ-DP complex region on human chromosome 6, with the class II region shown in greater detail below
Fig. 2 Map of the HLA DR-DQ-DP complex region on human chromosome 6, with the class II region shown in greater detail belowCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 127 references

Cited by

See all 198

Metadata

Authors
Regnell, S. E., & Lernmark, Å.
Affiliations
Lund University (SE)
Corresponding author
Lernmark, Åke
Venue
Diabetologia
Published
2017-05-26
Volume
60
Issue
8
Pages
1370-1381
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2620432821
Cited by
195
References
127
Citations by year
2026: 8 · 2025: 12 · 2024: 16 · 2023: 26 · 2022: 30 · 2021: 41 · 2020: 20 · 2019: 20 · 2018: 17 · 2017: 5
FWCI
2.19
Type
journal article
Language
en
Open access
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
Lund University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
type 1 diabetes, early prediction, insulin autoantibodies, glutamic acid decarboxylase antibodies, HLA-DQ8, HLA-DQ2, HLA class II, beta-cell mass loss, islet infiltration, mononuclear cell infiltration, type 1 diabetes prevention, genetic susceptibility
MeSH terms
Autoantibodies, Child, Diabetes Mellitus, Type 1, Female, Glutamate Decarboxylase, Humans, Insulin Antibodies, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early prediction of autoimmune (type 1) diabetes. https://app.cochat.ai/papers/10.1007/s00125-017-4308-1
The paper
Regnell, S. E., & Lernmark, Å. (2017). Early prediction of autoimmune (type 1) diabetes. Diabetologia. https://doi.org/10.1007/s00125-017-4308-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.